Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Nutra Pharma Corp. (NPHC)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0015+0.0006 (+66.67%)
At close: 12:45PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0009
Open0.0009
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0007 - 0.0015
52 Week Range0.0002 - 0.0087
Volume555,100
Avg. Volume730,788
Market Cap10.989M
Beta (5Y Monthly)2.63
PE Ratio (TTM)N/A
EPS (TTM)-0.0020
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Nutra Pharma Announces First Manufacturing Agreement

    Nutra Pharma is announcing Avini Health as its first contract manufacturing partnerPlantation, Florida, March 23, 2022 (GLOBE NEWSWIRE) -- Nutra Pharma Corporation (OTC Pink: NPHC), a biotechnology company marketing Nyloxin®, Pet Pain-Away™, Equine Pain-Away™ and Luxury Feet™ in the over-the-counter (OTC) pain management market and which is also developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV) and Pain, is announcing their first agreement to act as a product

  • GlobeNewswire

    Nutra Pharma Expands Manufacturing Capabilities

    Nutra Pharma is providing updates on their work in improving manufacturing scale and capabilities for new product launches for their OTC drugs and potential dietary supplementsPlantation, Florida, March 17, 2022 (GLOBE NEWSWIRE) -- Nutra Pharma Corporation (OTC Pink: NPHC), a biotechnology company marketing Nyloxin®, Pet Pain-Away™, Equine Pain-Away™ and Luxury Feet™ in the over-the-counter (OTC) pain management market and which is also developing treatments for Multiple Sclerosis (MS), Human Im

  • GlobeNewswire

    Nutra Pharma Letter to Shareholders

    Nutra Pharma has published their annual letter to shareholders to the Company’s websitePlantation, Florida, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Nutra Pharma Corporation (OTC Pink: NPHC), a biotechnology company marketing Nyloxin®, Pet Pain-Away™, Luxury Feet™ and Equine Pain-Away™ in the over-the-counter (OTC) pain management market and which is also developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV) and Pain, announced today that the Company's Chief Executive Of

Advertisement
Advertisement